TOKYO (Reuters) - Japan's Daiichi Sankyo Co said on Tuesday it was halting development of an existing drug for the treatment of COVID-19.
Daiichi Sankyo in March started a clinical trial in Japan of an inhaled form of nafamostat mesylate with COVID-19 patients. The company said in a statement it was discontinuing the trial without citing a reason. The Nikkei newspaper reported that there were safety concerns.
Nafamostat is used in the treatment of pancreatitis and has antiviral properties.
(Reporting by Rocky Swift, editing by Louise Heavens)
Price
|
Change
|
5d. change
|
Capi.
| ||
|---|---|---|---|---|---|
| 1,650 JPY | +0.49% | +0.64% | 2.33B | ||
| 37,552 PTS | +0.30% | -2.39% | - | ||
